P-393 A real-world UK experience of Daratumumab, Velcade, Dexamethasone and Carfilzomib, Lenalidomide, Dexamethasone as second line therapies in the UK: a South East London retrospective
Dogan Yildiz, Arief Gunawan(St Thomas' Hospital), Douglas Gunning(King's College Hospital), Madson Correia de Farias, Kirsty Cuthill, Sophie Deppe(King's College Hospital), Matthew Streetly(King's College - North Carolina), Sajitha Sachchithanantham(The Royal Free Hospital), Stella Bowcock(King's College Hospital), Katharine Bailey(King's College Hospital NHS Foundation Trust), Asma Batool, Sanela Kahrimanovic, María Cuadrado(University College London), Reuben Benjamin(King's College London), Youssef Salam, Paraskevi Gkreka(Princess Royal University Hospital)
Cited by 0
Related Papers
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
|The Lancet|2020|366
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
|Blood|2023|330
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315